AEterna Zentaris Inc. (AEZS) Sees Unusually-High Trading Volume

AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) shares saw unusually-strong trading volume on Monday . Approximately 950,750 shares changed hands during trading, a decline of 65% from the previous session’s volume of 2,745,090 shares.The stock last traded at $2.02 and had previously closed at $1.84.

A number of analysts have recently commented on AEZS shares. HC Wainwright set a $3.00 price objective on AEterna Zentaris and gave the stock a “buy” rating in a report on Wednesday, July 5th. Maxim Group set a $2.00 price objective on AEterna Zentaris and gave the stock a “buy” rating in a report on Saturday, July 1st. Zacks Investment Research upgraded AEterna Zentaris from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, ValuEngine upgraded AEterna Zentaris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. AEterna Zentaris presently has a consensus rating of “Hold” and a consensus target price of $4.00.

The company’s market capitalization is $32.22 million. The stock’s 50 day moving average is $1.94 and its 200 day moving average is $1.92.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.05). The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. AEterna Zentaris had a negative net margin of 1,945.78% and a negative return on equity of 514.64%. The business’s quarterly revenue was up 153.1% on a year-over-year basis. Analysts anticipate that AEterna Zentaris Inc. will post ($1.02) earnings per share for the current year.

WARNING: This piece was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply